所有人群中慢性移植物抗宿主病发生率持续下降
该研究在弗雷德·哈钦森癌症中心分析了2005至2019年间3066例造血干细胞移植存活者,发现需要全身免疫抑制治疗的慢性移植物抗宿主病(cGVHD-IS)的2年概率从45%-52%(2005-2007年)降至约40%(2008-2012年),到2017年进一步降至约26%。移植日期每增加5年,cGVHD的病因特异性风险降低27%(未调整HR 0.73,95%CI 0.68-0.78,P<.0001),调整多种因素后HR为0.81(95%CI 0.75-0.87,P<.0001)。
要点
- 2005至2019年间,所有存活者中cGVHD-IS的2年概率从45%-52%降至约26%。
- 儿童存活者中cGVHD-IS概率自2013年以来低于10%。
- 移植日期每增加5年,cGVHD病因特异性风险降低27%(未调整HR 0.73)。
核心结论
- cGVHD发生率下降的趋势未被人口学变化和更多使用通常与较低cGVHD发生率相关的移植方式完全解释。
- 该观察强调单队列cGVHD预防研究应使用同期对照而非历史对照进行比较。
研究设计与样本
- 研究纳入2005年至2019年间在弗雷德·哈钦森癌症中心接受造血干细胞移植的3066例存活者,分析需要全身免疫抑制治疗的cGVHD(cGVHD-IS)风险与移植日期的关系。
- 采用Cox回归模型评估移植日期(作为连续线性变量)与cGVHD病因特异性风险的关联,使用未调整和调整模型。
- 中位随访时间为7.0年(范围1.0-17.2年)。
主要发现
- 所有存活者中cGVHD-IS的2年概率从45%-52%(2005-2007年)降至约40%(2008-2012年),到2017年进一步降至约26%。
- 在502例儿童存活者中同样观察到下降,自2013年以来cGVHD-IS概率低于10%。
- 在305例因非恶性疾病接受移植的成人和儿童存活者中,cGVHD发生率波动较大,但2016年后保持在20%以下。
- 移植日期每增加5年,cGVHD的病因特异性风险降低27%(未调整HR 0.73;95%CI 0.68-0.78;P<.0001)。
- 调整年龄、供者/干细胞来源、种族、性别、预处理强度、GVHD预防等多种因素后,HR为0.81(95%CI 0.75-0.87;P<.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD requiring systemic immunosuppression (cGVHD-IS) as a function of hematopoietic cell transplantation (HCT) date in 3066 survivors from 2005 through 2019. Cox regression models were fit to assess associations of HCT date (as a continuous linear variable) with cause-specific hazards of cGVHD using unadjusted and adjusted models. Median follow-up for study subjects was 7.0 years (range, 1.0-17.2). Two-year probabilities of cGVHD-IS declined among all survivors from 45% to 52% (2005-2007) to ∼40% (2008-2012) and then further to ∼26% by 2017. A decline was also observed when the analysis was restricted to 502 pediatric survivors, with cGVHD-IS probabilities <10% since 2013. Among 305 adult and pediatric survivors who underwent transplantation for nonmalignant diseases, cGVHD rates showed greater fluctuation but remained <20% after 2016. Each 5-year increase in HCT date was associated with a 27% decrease in the cause-specific hazard of cGVHD (unadjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.68-0.78; P < .0001); the HR was 0.81 (95% CI, 0.75-0.87; P < .0001) even after adjusting for various factors (age, donor/stem-cell source, race, sex, conditioning intensity, GVHD prophylaxis, among others) that could lead to cGVHD reduction. The decline in cGVHD was not fully explained by demographic shifts and greater use of HCT approaches that are generally associated with lower cGVHD rates. This observation underscores that single-cohort cGVHD prevention studies should use contemporaneous and not historical controls for comparison.
引用
- Carpenter PA, Gooley TA, Boiko J, et al. Decreasing chronic graft-versus-host disease rates in all populations. Blood Adv. 2024. PMID: 39167805. doi:10.1182/bloodadvances.2024012722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。